TrialClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2021

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.

Florence Ader et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.